Characteristics of apparently healthy individuals with a very low C-reactive protein. 2019

Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, P.O.B. 39040, Tel Aviv 6997801, Israel. Electronic address: zivtome@post.tau.ac.il.

BACKGROUND The importance of the inflammatory processes and C-reactive protein (CRP) evaluation was observed. Only few studies used cut-off value <1 mg/L. We sought to evaluate the association between very low CRP (vlCRP) and health status, to describe the repetition of vlCRP and to identify predictors for repetition. METHODS A historical cohort study of all participants who underwent a routine annual check-up between January 2002 and July 2018 at the Tel Aviv Sourasky medical center. CRP test was evaluated in all participants. Individuals who use statins or with CRP >10 mg/L were excluded. CRP ≤0.12 mg/L was considered as vlCRP. RESULTS The final study cohort included 14,161 individuals. Of them, 5065 were females and mean age was 43.4 years (SD 10.6). vlCRP at first check-up was observed in 1299 (9.2%) of the participants. In multivariable analysis, older age, hyperlipidemia, hypertension and smoking were significantly associated with lower probability of vlCRP. At the second check-up, 50.1% vlCRP repetition was observed with no significant predictor from previous visit. CONCLUSIONS vlCRP is associated with younger age, non-smoking, and absence of hyperlipidemia and of hypertension. However, it may also be part of the individual physiology.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001774 Blood Chemical Analysis An examination of chemicals in the blood. Analysis, Blood Chemical,Chemical Analysis, Blood,Analyses, Blood Chemical,Blood Chemical Analyses,Chemical Analyses, Blood
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D005260 Female Females
D006304 Health Status The level of health of the individual, group, or population as subjectively assessed by the individual or by more objective measures. General Health,General Health Level,General Health Status,Level of Health,Overall Health,Overall Health Status,General Health Levels,Health Level,Health Level, General,Health Levels,Health Status, General,Health Status, Overall,Health, General,Health, Overall,Level, General Health,Levels, General Health,Status, General Health,Status, Health,Status, Overall Health
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016017 Odds Ratio The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases. Cross-Product Ratio,Risk Ratio,Relative Odds,Cross Product Ratio,Cross-Product Ratios,Odds Ratios,Odds, Relative,Ratio, Cross-Product,Ratio, Risk,Ratios, Cross-Product,Ratios, Risk,Risk Ratios
D064368 Healthy Volunteers Persons with no known significant health problems who are recruited to participate in research to test a new drug, device, or intervention as controls for a patient group. (from http://clinicalcenter.nih.gov/recruit/volunteers.html, accessed 2/14/2013) Healthy Participants,Healthy Subjects,Human Volunteers,Normal Volunteers,Healthy Participant,Healthy Subject,Healthy Volunteer,Human Volunteer,Normal Volunteer,Participant, Healthy,Participants, Healthy,Subject, Healthy,Subjects, Healthy,Volunteer, Healthy,Volunteer, Human,Volunteer, Normal,Volunteers, Human,Volunteers, Normal

Related Publications

Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
January 2007, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals,
Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
May 2004, Arteriosclerosis, thrombosis, and vascular biology,
Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
January 1968, Acta pathologica et microbiologica Scandinavica,
Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
February 2010, Arquivos brasileiros de cardiologia,
Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
April 2015, The Israel Medical Association journal : IMAJ,
Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
January 2004, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals,
Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
March 2006, International journal of cardiology,
Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
January 2005, The American journal of cardiology,
Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
November 1999, The American journal of cardiology,
Tomer Ziv-Baran, and Asaf Wasserman, and Ilana Goldiner, and Moshe Stark, and Shani Shenhar-Tsarfaty, and Itzhak Shapira, and David Zeltser, and Inna Mailis, and Shlomo Berliner, and Ori Rogowski
May 1982, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!